Proactively manage your pharmacy inventory
Anticipate generic drug launch
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Drug patents …
… from Kazakhstan to Kalamazoo
Manage your formulary budget
Find generic entry opportunities
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Abstract:||A hirudin derivative which has the N-terminal amino acid sequence Leu-Thr-Tyr-Thr-Asp shows high biological activity. Moreover, this hirudin derivative can be obtained very efficiently by genetic engineering preparation in yeasts.|
|Inventor(s):||Crause; Peter (Offenbach, DE), Habermann; Paul (Frankfurt am Main, DE), Tripier; Dominique (Eppstein/Taunus, DE)|
|Assignee:||Hoechst Aktiengesellschaft (Frankfurt am Main, DE)|
Patent Claim Types:|
see list of patent claims
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|Germany||3805540||Feb 23, 1988|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|European Patent Office||0324712||► subscribe||56/1997||Austria||► subscribe|
|European Patent Office||0324712||► subscribe||97C0046||Belgium||► subscribe|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.